Drug Manufacturers - General · NASDAQ
当前价格
$348.77
内在价值
使用下方计算器估算
对 Amgen Inc. 运行 PE 市盈率估值,自动填充盈利数据,可调节目标 PE,即时获得公允价值估算。
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Earnings Yield
4.10%
ROE (TTM)
96.7%
基于过去 12 个月的数据,AMGN 每股收益为 N/A,市盈率为 N/A。 这些是使用 PE 市盈率方法进行股票估值的关键输入。
AMGN 的过去 12 个月市盈率反映投资者为 Amgen Inc. 每一美元收益所支付的价格。该指标在与Drug Manufacturers - General同类公司和公司自身历史区间对比时最有意义。
AMGN 是否被高估取决于将其市盈率与Drug Manufacturers - General同类公司、历史均值和增长预期比较。高于行业均值的 PE 可能暗示高估,但高增长公司通常有更高的估值倍数。建议配合 DCF 模型获得更完整的判断。
对 Amgen Inc. 使用 PE 估值的步骤:(1) 将当前市盈率与Drug Manufacturers - General中位数对比评估相对定价,(2) 查看 PEG 比率以调整增长预期,(3) 参考 5 年 PE 历史区间判断当前位置,(4) 用目标 PE 乘以前瞻 EPS 估算公允价值。这种相对估值方法与 DCF 的绝对估值互为补充。
PEG 比率将市盈率除以预期盈利增速,提供增长调整后的估值指标。PEG 低于 1.0 可能表明相对于增长被低估,高于 2.0 可能暗示高估。PEG 对盈利增长稳定可预测的公司最为可靠。
PE 市盈率给出快速的相对定价——AMGN 相对于Drug Manufacturers - General同类的估值水平。DCF 基于预期自由现金流提供绝对价值。对于 AMGN,ROE 达到 96.7%,两种方法都值得使用——PE 做市场对比,DCF 验证基本面是否支撑当前价格。两种方法各有盲区:PE 忽略了资本结构和现金流质量,DCF 则对增长率和折现率假设非常敏感。